MYC, PARP1, and chemoresistance: BIN there, done that?

Science Signaling

Volumn 4, Issue 166, 2011, Pages

  Ganesan, Shridar ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BRIDGING INTEGRATOR 1 PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR MYC INTERACTING ZINC FINGER 1; UNCLASSIFIED DRUG; XRCC1 PROTEIN; BIN1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

BIOTRANSFORMATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHEMORESISTANCE; CHEMOSENSITIVITY; CHROMATIN STRUCTURE; COMPETITIVE INHIBITION; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GENE AMPLIFICATION; HUMAN; IN VITRO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REGULATORY MECHANISM; REVIEW; TELOMERE; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEAR PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEINS;

EID: 79953240108     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001946     Document Type: Review

References (33)

1. K. Goda, Z. Bacsó, G. Szabó, Multidrug resistance through the spectacle of P-glycoprotein. Curr. Cancer Drug Targets 9, 281-297 (2009).
2. M. T. Kuo, Roles of multidrug resistance genes in breast cancer chemoresistance. Adv. Exp. Med. Biol. 608, 23-30 (2007).
3. H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin, T. Helleday, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
4. H. Farmer, N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith, A. Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
5. S. A. Martin, C. J. Lord, A. Ashworth, DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 18, 80-86 (2008).
6. S. Pyndiah, S. Tanida, K. M. Ahmed, E. K. Cassimere, D. Ssakamuro, C-MYC supresses BIN1 to release poly(ADP-ribose) polymerase 1: A mechanism by which Cancer cells acquire cisplatin resistance. Sci. Signal. 4, ra19 (2011).
7. G. C. Prendergast, A. J. Muller, A. Ramalingam, M. Y. Chang, BAR the door: Cancer suppression by amphiphysin-like genes. Biochim. Biophys. Acta 1795, 25-36 (2009).
8. G. Ren, P. Vajjhala, J. S. Lee, B. Winsor, A. L. Munn, The BAR domain proteins: molding membranes in fission, fusion, and phagy. Microbiol. Mol. Biol. Rev. 70, 37-120 (2006).
9. R. Wechsler-Reya, D. Sakamuro, J. Zhang, J. Duhadaway, G. C. Prendergast, Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J. Biol. Chem. 272, 31453-31458 (1997).
10. D. Sakamuro, K. J. Elliott, R. Wechsler-Reya, G. C. Prendergast, BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Genet. 14, 69-77 (1996).
11. J. B. DuHadaway, F. J. Lynch, S. Brisbay, C. Bueso-Ramos, P. Troncoso, T. McDonnell, G. C. Prendergast, Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J. Cell. Biochem. 88, 635-642 (2003).
12. K. Ge, J. DuHadaway, W. Du, M. Herlyn, U. Rodeck, G. C. Prendergast, Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl. Acad. Sci. U.S.A. 96, 9689-9694 (1999).
13. M. D. Hogarty, X. Liu, P. M. Thompson, P. S. White, E. P. Sulman, J. M. Maris, G. M. Brodeur, BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Med. Pediatr. Oncol. 35, 559-562 (2000).
14. A. Ghaneie, V. Zemba-Palko, H. Itoh, K. Itoh, D. Sakamuro, S. Nakamura, A. P. Soler, G. C. Prendergast, Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol. Ther. 6, 192-194 (2007).
15. T. Tajiri, X. Liu, P. M. Thompson, S. Tanaka, S. Suita, H. Zhao, J. M. Maris, G. C. Prendergast, M. D. Hogarty, Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin. Cancer Res. 9, 3345-3355 (2003).
16. E. B. Kuznetsova, T. V. Kekeeva, S. S. Larin, V. V. Zemlyakova, A. V. Khomyakova, O. V. Babenko, M. V. Nemtsova, D. V. Zaletayev, V. V. Strelnikov, Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J. Carcinog. 6, 9 (2007).
17. B. C. Woodhouse, G. L. Dianov, Poly ADP-ribose polymerase-1: An international molecule of mystery. DNA Repair (Amst.) 7, 1077-1086 (2008).
18. S. L. Oei, C. Keil, M. Ziegler, Poly(ADP-ribosylation) and genomic stability. Biochem. Cell Biol. 83, 263-269 (2005).
19. T. Helleday, H. E. Bryant, N. Schultz, Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4, 1176-1178 (2005).
20. I. Ahel, D. Ahel, T. Matsusaka, A. J. Clark, J. Pines, S. J. Boulton, S. C. West, Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451, 81-85 (2008).
21. M. S. Satoh, T. Lindahl, Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 356-358 (1992).
22. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, R. A. Sharma, DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193-204 (2008).
23. Y. Ji, A. V. Tulin, The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Dev. 20, 512-518 (2010).
24. W. L. Kraus, Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr. Opin. Cell Biol. 20, 294-302 (2008).
25. K. Elliott, D. Sakamuro, A. Basu, W. Du, W. Wunner, P. Staller, S. Gaubatz, H. Zhang, E. Prochownik, M. Eilers, G. C. Prendergast, Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 18, 3564-3573 (1999).
26. M. D. Sklar, E. V. Prochownik, Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 51, 2118-2123 (1991).
27. C. Leonetti, A. Biroccio, A. Candiloro, G. Citro, C. Fornari, M. Mottolese, D. Del Bufalo, G. Zupi, Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin. Cancer Res. 5, 2588-2595 (1999).
28. A. Ramalingam, G. E. Farmer, T. D. Stamato, G. C. Prendergast, Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle 6, 1914-1918 (2007).
29. E. K. Cassimere, S. Pyndiah, D. Sakamuro, The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 16, 1641-1653 (2009).
30. J. O'Shaughnessy, C. Osborne, J. E. Pippen, M. Yoffe, D. Patt, C. Rocha, I. C. Koo, B. M. Sherman, C. Bradley, Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
31. S. Chandriani, E. Frengen, V. H. Cowling, S. A. Pendergrass, C. M. Perou, M. L. Whitfield, M. D. Cole, A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE 4, e6693 (2009).
32. M. C. Alles, M. Gardiner-Garden, D. J. Nott, Y. Wang, J. A. Foekens, R. L. Sutherland, E. A. Musgrove, C. J. Ormandy, Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS ONE 4, e4710 (2009).
33. Funding: S.G. has received support from the National Institutes of Health, the U.S. Department of Defense, the New Jersey Commission on Cancer Research, and the Triple-Negative Breast Cancer Foundation.